Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

[1]  G. Bevilacqua,et al.  Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. , 1998, European journal of cancer.

[2]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[3]  S Charrier,et al.  Clinical and pathological response to primary chemotherapy in operable breast cancer. , 1997, European journal of cancer.

[4]  A. Vincent-Salomon,et al.  ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. , 2000, European journal of cancer.

[5]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[6]  J. Bergh,et al.  Clinical studies of p53 in treatment and benefit of breast cancer patients. , 1999, Endocrine-related cancer.

[7]  Henry M Kuerer,et al.  Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline‐based neoadjuvant chemotherapy in patients with breast carcinoma , 2002, Cancer.

[8]  L. Skoog,et al.  Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. , 1999, Acta oncologica.

[9]  J. Bryant,et al.  Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. , 2002, Cancer.

[10]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[11]  N Gunduz,et al.  Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. , 1983, Cancer research.

[12]  A. Goldhirsch,et al.  Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.

[13]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. , 1978, European journal of cancer.

[14]  G. Giaccone,et al.  Expression of drug resistance proteins in breast cancer, in relation to chemotherapy , 1997, International journal of cancer.

[15]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[16]  M. Merino,et al.  The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. , 1990, Human pathology.

[17]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[18]  C. Quinn,et al.  Effects of chemotherapy on breast cancer tissue , 1997, Histopathology.

[19]  A. Cruz,et al.  Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  J. Bryant,et al.  Pathobiology of preoperative chemotherapy , 2002 .

[21]  T. Powles,et al.  A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Piccart,et al.  The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  K. Franssila,et al.  Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. , 1997, British Journal of Cancer.

[24]  S. Jaffer,et al.  Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer * , 2002, Journal of surgical oncology.

[25]  M. Daidone,et al.  Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. , 1999, Endocrine-related cancer.

[26]  F. Gago,et al.  c‐erbB‐2 (HER‐2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy , 1999, International journal of cancer.

[27]  B. Gusterson,et al.  High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[29]  N. Kapucuoglu,et al.  The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer , 1996, Histopathology.

[30]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[31]  N Gunduz,et al.  Effect of surgical removal on the growth and kinetics of residual tumor. , 1979, Cancer research.

[32]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[33]  J. Schneider,et al.  Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. , 2000, Anticancer research.

[34]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[35]  T. Powles,et al.  Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study , 2004, Breast Cancer Research and Treatment.

[36]  H. Frierson,et al.  Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. , 1994, American journal of clinical pathology.

[37]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[38]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. J. van de Vijver,et al.  Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  P. V. van Diest,et al.  Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. , 1997, American journal of clinical pathology.

[41]  G. MacGrogan,et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.